The next-generation GLP-1 pipeline
Written by
glpzoom Editorial Team
Medically reviewed
Against primary clinical sources- ~0%
- retatrutide max weight loss in trials
- Apr 0 2026
- orforglipron FDA PDUFA
- $0/mo
- orforglipron launch price
- 07
- retatrutide expected launch
Today's GLP-1s already produce 15-21% mean weight loss. The next wave pushes higher and, just as importantly, moves beyond the weekly injection. Here's what's actually in late-stage development, with honest timelines, none of these is a reason to wait if you qualify for a treatment available today.
Orforglipron
Eli LillyOral non-peptide GLP-1
Status: FDA decision April 2026; launching via LillyDirect
~14-15% mean weight loss; first true daily pill without Rybelsus's fasting rules
Full Orforglipron page →Retatrutide
Eli LillyTriple agonist (GLP-1 / GIP / glucagon)
Status: Phase 3 (TRIUMPH); expected ~2027
~24% mean weight loss at the highest dose, the largest class signal reported to date
Full Retatrutide page →CagriSema
Novo NordiskSemaglutide + cagrilintide (amylin analog)
Status: Phase 3; filings expected 2026-2027
Combines GLP-1 with an amylin pathway; trials targeting tirzepatide-level loss
Oral semaglutide 25mg (oral Wegovy)
Novo NordiskOral GLP-1 peptide (high-dose)
Status: FDA-approved 2026; distribution ramping
Brings injectable-level semaglutide to a daily tablet, with strict dosing rules
Full Oral semaglutide 25mg (oral Wegovy) page →A safety note: investigational drugs like retatrutide are not legally for sale. Any website offering to ship “retatrutide” today is operating outside the law and outside FDA safety oversight. The only legitimate access is a clinical trial.